About Peptide Therapeutics
Peptides are amino acids sequences and among the most potent biologically active substances found in nature. Peptides are used to control, trigger, and maintain physiological processes in living beings. However, the use of peptides as therapeutic agents has always been difficult because of their inherent instability and incapability to cross cellular membranes. Peptides also entail the requirement of specific technology to tackle the extensive and challenging steps in their synthesis. Currently, there are more than 80 peptides marketed by various companies. These companies explore the probability of designing and engineering peptides that overcome their natural confines and allow these potent chemical entities to be used as therapeutic agents.
TechNavio's analysts forecast the Global Peptide Therapeutics market to grow at a CAGR of 9.25 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Peptide Therapeutics market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various approved peptide drugs to treat individuals against various diseases, such as, cardiovascular, metabolic, neurological, respiratory, and others.
TechNavio's report, the Global Peptide Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Peptide Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• EMEA
• APAC
Key Vendors
• AstraZeneca
• Eli Lilly
• Novo Nordisk
• Sanofi
Other Prominent Vendors
• Abbvie
• Advanced Accelerator Applications
• Akashi Therapeutics
• Amylin
• Anthera Pharmaceuticals
• AstraZeneca
• Bachem
• Bristol Myers Squibb
• Cardiorentis
• Cubist Pharmaceuticals
• Diartis Pharmaceuticals
• Debiopharm
• Derma Sciences
• GlaxoSmithKline
• Hanmi Pharmaceutical
• Insmed
• Ipsen
• Johnson & Johnson
• Lonza
• Mallinckrodt
• MolMed
• Merck
• Novartis
• Nymox Pharmaceutical
• Par Pharmaceuticals
• PeptiDream
• Peptisyntha
• Polypeptide Group
• Radius Health
• Repligen
• SciClone
• Shire
• Takeda Pharmaceutical
• The Medicines Company
• Transition Therapeutics
• X-Gen Pharmaceuticals
• Zealand Pharma
• Zydus Cadila
Market Driver
• Rising Patient Population
• For a full, detailed list, view our report
Market Challenge
• High Cost of Therapy
• For a full, detailed list, view our report
Market Trend
• Growing Popularity
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Route of Administration
07.1 Parenteral
07.2 Oral
07.3 Pulmonary
07.4 Mucosal
08. Market Segmentation by Drug Class
08.1 Somatostatins
08.2 Vasopressins
08.3 Calcitonins
08.4 LHRH
08.5 Glucagon and Analogs
08.6 Insulins
08.7 Others
09. Market Segmentation by Technology
09.1 Liquid Phase Peptide Synthesis
09.2 Solid Phase Peptide Synthesis
09.3 Hybrid Synthesis
10. Geographical Segmentation
10.1 Peptide Therapeutics Market in the Americas
10.1.1 Market Size and Forecast
10.2 Peptide Therapeutics Market in the EMEA
10.2.1 Market Size and Forecast
10.3 Peptide Therapeutics Market in APAC
10.3.1 Market Size and Forecast
11. Peptide Synthesis
12. Optimization of Peptides
12.1 Ligation
12.2 Cyclization
12.3 Heterodimerization
12.4 Cytoconjugation
13. Stabilization of Peptides
13.1 Stapled Peptides
13.2 Disulfide-rich Peptides
13.3 Other Constrained Peptides
14. Buying Criteria
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2013
21.3 Other and Future Prominent Vendors
22. Pipeline Portfolio
23. Key Vendor Analysis
23.1 AstraZeneca
23.1.1 Key Facts
23.1.2 Business Description
23.1.3 Business Segmentation
23.1.4 Business Strategy
23.1.5 Revenue by Business Segmentation
23.1.6 Revenue Comparison 2011-2013
23.1.7 Sales Revenue by Geographical Segmentation
23.1.8 Key Developments
23.1.9 SWOT Analysis
23.2 Eli Lilly
23.2.1 Key Facts
23.2.2 Business Overview
23.2.3 Business Segmentation by Revenue 2013
23.2.4 Business Segmentation by Revenue 2012 and 2013
23.2.5 Sales by Geography
23.2.6 Business Strategy
23.2.7 Key Developments
23.2.8 SWOT Analysis
23.3 Novo Nordisk
23.3.1 Key Facts
23.3.2 Business Overview
23.3.3 Business Segmentation
23.3.4 Business Strategy
23.3.5 Revenue Segmentation by Business
23.3.6 Revenue Comparison by Business Segments 2012 and 2013
23.3.7 Sales by Geography
23.3.8 Key Information
23.3.9 SWOT Analysis
23.4 Sanofi
23.4.1 Key Facts
23.4.2 Business Overview
23.4.3 Business Segmentation by Revenue 2013
23.4.4 Business Segmentation by Revenue 2012 and 2013
23.4.5 Geographical Segmentation by Revenue 2013
23.4.6 Business Strategy
23.4.7 Key Developments
23.4.8 SWOT Analysis
24. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Peptide Therapeutics Market 2013-2018 (US$ billion)
Exhibit 3: Global Peptide Therapeutics Market Segmentation by Route of Administration
Exhibit 4: Global Peptide Therapeutics Market Segmentation by Route of Administration 2013
Exhibit 5: Global Peptide Therapeutics Market Segmentation by Class of Drugs
Exhibit 6: Global Peptide Therapeutics Market Segmentation by Technology
Exhibit 7: Global Peptide Therapeutics Market by Geographical Segmentation 2013
Exhibit 8: Peptide Therapeutics Market in Americas 2013-2018 (US$ billion)
Exhibit 9: Peptide Therapeutics Market in EMEA 2013-2018 (US$ billion)
Exhibit 10: Peptide Therapeutics Market in APAC 2013-2018 (US$ billion)
Exhibit 11: Steps involved in Peptide Synthesis
Exhibit 12: Optimization of Peptide Synthesis
Exhibit 13: Methods used for Stabilization of Peptides
Exhibit 14: Global Peptide Therapeutics Market Segmentation 2013
Exhibit 15: Therapeutic Areas for Peptides in Clinical Studies 2013
Exhibit 16: Peptide Therapeutics in Phase III Clinical Trials, 2013
Exhibit 17: Peptide Therapeutics Under Clinical Trials According to MOA
Exhibit 18: AstraZeneca: Business Segmentation
Exhibit 19: AstraZeneca: Revenue by Business Segmentation 2013
Exhibit 20: AstraZeneca: Revenue by Business Segmentation 2011-2013 (US$ billion)
Exhibit 21: AstraZeneca: Sales Revenue by Geographical Segmentation 2013
Exhibit 22: Eli Lilly and Co.: Business Segmentation by Revenue 2013
Exhibit 23: Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 24: Eli Lilly and Co.: Sales by Geography 2013
Exhibit 25: Business Segments of Novo Nordisk A/S 2013
Exhibit 26: Novo Nordisk A/S: Business Segmentation 2013
Exhibit 27: Novo Nordisk A/S: Revenue Comparison 2012 and 2013 (US$ billion)
Exhibit 28: Novo Nordisk A/S: Sales by Geography 2013
Exhibit 29: Sanofi: Business Segmentation by Revenue 2013
Exhibit 30: Sanofi: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 31: Sanofi: Geographical Segmentation by Revenue 2013
